Gutierrez Juan Pablo, Johns Benjamin, Adam Taghreed, Bertozzi Stefano M, Edejer Tessa Tan-Torres, Greener Robert, Hankins Catherine, Evans David B
Division of Health Economics and Policy, National Institute of Public Health, Cuernavaca, Mexico.
Lancet. 2004;364(9428):63-4. doi: 10.1016/S0140-6736(04)16590-2.
The "3 by 5" goal to have 3 million people in low and middle income countries on antiretroviral therapy (ART) by the end of 2005 is ambitious. Estimates of the necessary resources are needed to facilitate resource mobilisation and rapid channelling of funds to where they are required. We estimated the financial costs needed to implement treatment protocols, by use of country-specific estimates for 34 countries that account for 90% of the need for ART in resource-poor settings. We first estimated the number of people needing ART and supporting programmes for each country. We then estimated the cost per patient for each programme by country to derive total costs. We estimate that between US5.1 billion dollars and US5.9 billion dollars will be needed by the end of 2005 to provide ART, support programmes, and cover country-level administrative and logistic costs for 3 by 5.
“三五”目标是到2005年底使低收入和中等收入国家300万人接受抗逆转录病毒治疗(ART),这一目标雄心勃勃。需要对所需资源进行估算,以促进资源筹集并将资金迅速输送到所需之处。我们利用34个国家的国别估算数据,对实施治疗方案所需的财务成本进行了估算,这34个国家占资源匮乏地区抗逆转录病毒治疗需求的90%。我们首先估算了每个国家需要抗逆转录病毒治疗及支持项目的人数。然后,我们按国家估算了每个项目的人均成本,以得出总成本。我们估计,到2005年底,为实现“三五”目标提供抗逆转录病毒治疗、支持项目以及支付国家层面行政和后勤成本将需要51亿至59亿美元。